Constantine Cannon (New York)

Ankur Kapoor

Constantine Cannon (New York)

Ankur Kapoor is a partner at Constantine Cannon and has been at the firm since 2004, focusing on antitrust litigation and counseling. Ankur is an active member of the American Bar Association’s Section of Antitrust Law. He was an Editor of Antitrust Law Developments (7th ed. 2012) and currently serves as a Vice Chair of the Media and Technology Committee. Ankur is a graduate of the New York University School of Law, where he was a member of the National Moot Court Competition Team. He holds a B.A. from Columbia University, where he majored in Economics and minored in Computer Science. Ankur is admitted to practice in New York State, the United States District Courts for the Eastern and Southern Districts of New York, and the United States Court of Appeals for the Second Circuit.


Auteurs associés

Constantine Cannon (New York)
Constantine Cannon (Washington)
Constantine Cannon (Washington)
Constantine Cannon (Washington)
Constantine Cannon (Washington)


1082 Bulletin

Allison F. Sheedy, Ethan Litwin, Ankur Kapoor The US District Court for the Northeastern District of New York dismisses a drug manufacturer’s claim against a rival which it alleged blocked entry into the market for a medication administered through pre-loaded syringes (Novartis / Regeneron)


A Nearsighted Approach to Product Market Definition : Court Rejects Low-Cost Rival’s Antitrust Claims Alleging Novartis Blocked Competition in the Sale of Eye-Disease Treatments* One antitrust case we have been watching closely is the patent-related antitrust suit filed by biotechnology (...)

Ankur Kapoor The US FTC files a complaint before the District Court for the Eastern District of Pennsylvania asserting that reverse payments do not have to be cash or money in order to violate antitrust laws (AbbVie)


Regulators Prescribing Higher Dose Of Pharmaceutical Antitrust Enforcement* Antitrust enforcers returned to their offices after Labor Day, refreshed and ready to tackle what they view to be anticompetitive practices by pharmaceutical companies to delay entry of lower-priced generic drugs. (...)


Total des visites

Nombre de lectures par contribution

Nombre de contributions

Classement de l'auteur
En nombre de contributions
En nombre total de visites
En nombre moyen de visites
Envoyer un message